2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Outstanding mix of clinical abstracts, including clinical trials, retrospective analysis, and molecular observations in myelofibrosis, polycythemia vera, essential thrombocythemia and other myeloid neoplasms
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2004 PPM1D mutations in myeloid neoplasms: Morphologic spectrum, co-mutation patterns, and clinical correlates

Aysel Bayraktar, Muhammad Yousuf2, Shraddha Patel3, Cinthya J. Zepeda Mendoza4, Kaaren Reichard, MD5, David Viswanatha, MD6, Rong He, MD7, Animesh Pardanani, PhD, MBBS8, Devendra Hiwase I, Consultant Haematologist9, Mithun Shah, MD, PhD10, Naseema Gangat, MBBS11, Talha Badar, MD12, Ayalew Tefferi, MD13
1 Mayo Clinic, Rochester, MN, United States
2 Mayo Clinic, Rochester, MN, United States
3 Mayo Clinic, Rochester, MN, United States
4 Mayo Clinic, Rochester, MN, United States
5 Mayo Clinic, Rochester, MN, United States
6 Mayo Clinic, Rochester, MN, United States
7 Mayo Clinic, Rochester, MN, United States
8 Mayo Clinic, Rochester, MN, United States
9 Royal Adelaide Hospital and South Australian Health, Adelaide, Australia
10 Mayo Clinic, Rochester, MN, United States
11 Mayo Clinic, Rochester, MN, United States
12 Mayo Clinic, Rochester, MN, United States
13 Mayo Clinic, Rochester, MN, United States

Background:

PPM1D encodes the wild-type p53 inducible phosphatase that functions as a negative regulator of the DNA damage response. PPM1D mutations (PPM1DMUT) have been described in a spectrum of primary and secondary cancers and have been associated with poor survival. The objectives of the current retrospective study of pathogenic PPM1DMUT in myeloid neoplasms (MNs) were to i) describe associated morphologic diagnoses, stratified by history of chemo/radiotherapy, ii) estimate MN subtype-specified prevalence, iii) annotate mutation types, iv) outline genotype associations, and v) inspect MN subtype-stratified survival data.

Methods:

The study was conducted under institutional review board-approved minimum-risk protocols allowing retrospective patient data collection and analysis. Pathology diagnoses were rendered by Mayo Clinic board-certified hematopathologists following the 2022 ICC criteria (Arber et al. Blood 2022. 140:1200), with CLIA-approved NGS testing used to curate mutational data. For survival analysis, patients were censored at the time of allogeneic stem cell transplant (ASCT).

Results:

A Mayo Clinic enterprise-wide search of approximately 11,117 cases who underwent NGS evaluation for suspected or confirmed hematologic malignancy (2019–2025) identified 190 (1.7%) patients with pathogenic PPM1DMUT. Of these, 75 (0.7%) had MNs (median age 71 years; 63% male): 27 myelodysplastic syndromes (MDS: therapy -related [TR] 17), 26 myeloproliferative neoplasm (MPN: TR 3), 14 acute myeloid leukemia (AML) or MDS/AML (TR 8), and 8 chronic myelomonocytic leukemia (CMML: TR 2). The remaining 115 included 56 with CHIP, 44 with CCUS, and 15 with lymphoid malignancies. Seventy (93%) of the 75 patients with PPM1D-mutated MN harbored one, three had 2, and two >2 pathogenic PPM1D variants. All dominant mutations were C-terminal truncations within exon 6 with variant allele frequency <50%. Co-mutations were identified in 62 (83%), patients, while 13 harbored isolated PPM1DMUT. The most frequently co-mutated genes were JAK2 (28%), TP53 (27%), TET2 (17%), and ASXL1 (16%).

MN subtype-specific frequencies among tested cases were 3.6% in myelofibrosis (MF: 12/328), 4.7% in polycythemia vera (PV: 8/168), 3.6% in essential thrombocythemia (ET: 6/166), 6.6% in AML or MDS/AML (14/209), and 2% in CMML (8/399); a corresponding database cohort in MDS was unavailable for analysis. MN subtype-specified genotype comparisons between PPM1DMUT vs. wild-type (PPM1DWT) disclosed that PPM1DMUT was associated with TP53MUT in MF (25% vs. 2%; p<0.01) and CMML (25% vs. 2%; p=0.01), DNMT3AMUT (38% vs. 3%; p<0.01) in PV, and JAK2MUT in AML (19% vs. 3%; p≤0.01). PPM1DMUT was associated with older age in MF (72 vs. 68 years), ET (72 vs. 54 years), and AML (77 vs. 67 years; p≤0.03 in all instances). In analyses restricted to PPM1D-mutated cases, ASXL1 co-mutation was associated with de novo vs. therapy-related MDS (40% vs. 6%; p=0.02) and TP53 co-mutation with higher prevalence of complex karyotype (CK) in MDS (80% vs. 12%; p<0.01) and MPNs (50% vs. 4%; p=0.03).

Median overall survival was 13 months in MDS, 6 months in AML or AML/MDS, and not-reached in MPN or CMML. In univariate analysis, transplant-censored overall survival (TCOS), calculated from the time of NGS evaluation, was shorter in PPM1D-mutated vs. wild-type ET (2-year survival: 80% vs. 98%; p<0.01) and blast transformation rate higher in MF (2-year incidence: 29% vs.7%; p<0.01); both associations lost significance in multivariable analysis that adjusted for age, CK, and TP53 co-mutation. Among PPM1D-mutated cases, age adjusted TCOS was inferior in the presence of TP53 co-mutation in MDS or CMML (HR: 1.3; p=0.051) while it was comparable across other MNs (p=0.49 for MPNs; p=0.14 for AML or MDS/AML). Similarly, TCOS, in the context of PPM1D mutated disease, was comparable between de novo vs. therapy-related disease in MPN (p=0.49), although a numerically inferior trend was noted in MDS/CMML (p=0.17) and AML or MDS/AML (p=0.14).

Conclusion: PPM1DMUT is infrequent but evenly distributed across acute (frequency 6.6%) and chronic (2-5%) myeloid neoplasms with MN subtype-specific associations with TP53MUT (MF and CMML), DNMT3AMUT (PV), and JAK2MUT (AML). Associations with TP53MUT, CK, and older age appear to drive prognostic impact. Prognostic interaction with therapy-related disease warrants further investigation in larger datasets.

Aysel Bayraktar: No relevant conflicts of interest to declare.